A common CV risk factor calculator for patients with HIV underestimates risk for Black patients and women, while risk for ...

Gilead Sciences Inc. closed 1.35% below its 52-week high of $106.69, which the company achieved on February 14th.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

At the State of Black Health second annual summit hosted by BlackDoctor.org in partnership with USA TODAY, corporate leaders ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Fintel reports that on February 18, 2025, Deutsche Bank upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Hold ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

CompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...